KBM-5 cells treated with NPI-0052, TNF, thalidomide, and bortezomib alone or in combination
| NPI-0052, nM . | NPI-0052, % apoptosis . | TNF, % apoptosis . | Thalidomide, % apoptosis . | Bortezomib, % apoptosis . | |||
|---|---|---|---|---|---|---|---|
| 1 nM . | 5 nM . | 5 μg/mL . | 10 μg/mL . | 10 nM . | 20 nM . | ||
| 0 | 1 ± 0.6 | 12.3 ± 2.1 | 23.3 ± 4.2 | 7 ± 2 | 11.3 ± 3.5 | 6.7 ± 2.1 | 10.7 ± 2.1 |
| 25 | 7 ± 2 | 24 ± 5.3 | 36.7 ± 5.5 | 14 ± 4 | 26 ± 5.3 | 12.7 ± 3.1 | 33.7 ± 4 |
| 50 | 20.7 ± 4 | 65.3 ± 6.5 | 86.3 ± 3.5 | 36 ± 3.6 | 54.3 ± 4 | 29.7 ± 3.5 | 55.7 ± 2.1 |
| 100 | 40.7 ± 4 | 93 ± 2.0 | 98 ± 2.6 | 50 ± 3 | 88 ± 5.6 | 55.3 ± 3.5 | 91.3 ± 1.2 |
| NPI-0052, nM . | NPI-0052, % apoptosis . | TNF, % apoptosis . | Thalidomide, % apoptosis . | Bortezomib, % apoptosis . | |||
|---|---|---|---|---|---|---|---|
| 1 nM . | 5 nM . | 5 μg/mL . | 10 μg/mL . | 10 nM . | 20 nM . | ||
| 0 | 1 ± 0.6 | 12.3 ± 2.1 | 23.3 ± 4.2 | 7 ± 2 | 11.3 ± 3.5 | 6.7 ± 2.1 | 10.7 ± 2.1 |
| 25 | 7 ± 2 | 24 ± 5.3 | 36.7 ± 5.5 | 14 ± 4 | 26 ± 5.3 | 12.7 ± 3.1 | 33.7 ± 4 |
| 50 | 20.7 ± 4 | 65.3 ± 6.5 | 86.3 ± 3.5 | 36 ± 3.6 | 54.3 ± 4 | 29.7 ± 3.5 | 55.7 ± 2.1 |
| 100 | 40.7 ± 4 | 93 ± 2.0 | 98 ± 2.6 | 50 ± 3 | 88 ± 5.6 | 55.3 ± 3.5 | 91.3 ± 1.2 |
Data shown are means plus or minus the standard deviation.Cells (106/mL) were treated with indicated concentrations of NPI-0052, TNF, thalidomide, and bortezomib alone or in combination for 16 hours at 37oC. Cells were stained with a live/dead assay reagent for 30 minutes and then analyzed under a fluorescence microscope as described in ″Live and dead assay.″ The results shown are the percentage of apoptosis and are representative of 3 independent experiments.